DOP2022000122A - Analogos de incretina y sus usos - Google Patents
Analogos de incretina y sus usosInfo
- Publication number
- DOP2022000122A DOP2022000122A DO2022000122A DO2022000122A DOP2022000122A DO P2022000122 A DOP2022000122 A DO P2022000122A DO 2022000122 A DO2022000122 A DO 2022000122A DO 2022000122 A DO2022000122 A DO 2022000122A DO P2022000122 A DOP2022000122 A DO P2022000122A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- incretin analogs
- glucagon
- receptors
- activity
- incretin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Details Of Garments (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan los análogos de incretina que tienen actividad en cada uno de los receptores del polipéptido insulinotrópico dependiente de glucosa (GIP), el péptido similar a glucagón-1 (GLP-1) y el glucagón (GCG). Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan los métodos para tratar las enfermedades, tales como la diabetes mellitus tipo 2, la dislipidemia, el síndrome metabólico, la enfermedad del hígado graso no alcohólico, la esteatohepatitis no alcohólica y la obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949661P | 2019-12-18 | 2019-12-18 | |
| PCT/US2020/064512 WO2021126695A1 (en) | 2019-12-18 | 2020-12-11 | Incretin analogs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2022000122A true DOP2022000122A (es) | 2022-07-31 |
Family
ID=74181298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2022000122A DOP2022000122A (es) | 2019-12-18 | 2022-06-14 | Analogos de incretina y sus usos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230102339A1 (es) |
| EP (1) | EP4077365A1 (es) |
| JP (1) | JP7450724B2 (es) |
| KR (1) | KR20220100676A (es) |
| CN (1) | CN114787183A (es) |
| AR (1) | AR120714A1 (es) |
| AU (1) | AU2020408139B2 (es) |
| BR (1) | BR112022009396A2 (es) |
| CA (1) | CA3162245A1 (es) |
| CL (1) | CL2022001623A1 (es) |
| CO (1) | CO2022008264A2 (es) |
| CR (1) | CR20220279A (es) |
| DO (1) | DOP2022000122A (es) |
| EC (1) | ECSP22048612A (es) |
| IL (1) | IL293754A (es) |
| JO (1) | JOP20220153A1 (es) |
| MX (1) | MX2022007666A (es) |
| PE (1) | PE20221518A1 (es) |
| TW (1) | TWI795698B (es) |
| WO (1) | WO2021126695A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116710462A (zh) | 2021-01-20 | 2023-09-05 | 维京治疗公司 | 用于治疗代谢病症和肝病的组合物和方法 |
| KR20240099485A (ko) * | 2021-11-19 | 2024-06-28 | 메드샤인 디스커버리 아이엔씨. | 스테이플화 펩타이드 및 이의 용도 |
| WO2024163535A1 (en) | 2023-01-31 | 2024-08-08 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| WO2024213022A1 (zh) * | 2023-04-11 | 2024-10-17 | 上海多米瑞生物技术有限公司 | 肠促胰素类似物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| CN106029087A (zh) | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| DK3398961T3 (da) | 2015-12-31 | 2022-08-22 | Hanmi Pharm Ind Co Ltd | Tredobbelt aktivator, der aktiverer glukagon, glp 1 og gip-receptor |
| AR107890A1 (es) | 2016-03-10 | 2018-06-28 | Medimmune Ltd | Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad |
| TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2020
- 2020-12-10 AR ARP200103435A patent/AR120714A1/es unknown
- 2020-12-10 TW TW109143561A patent/TWI795698B/zh active
- 2020-12-11 JO JOP/2022/0153A patent/JOP20220153A1/ar unknown
- 2020-12-11 BR BR112022009396A patent/BR112022009396A2/pt unknown
- 2020-12-11 EP EP20839440.3A patent/EP4077365A1/en active Pending
- 2020-12-11 PE PE2022001115A patent/PE20221518A1/es unknown
- 2020-12-11 KR KR1020227020239A patent/KR20220100676A/ko not_active Application Discontinuation
- 2020-12-11 CN CN202080087802.4A patent/CN114787183A/zh active Pending
- 2020-12-11 CR CR20220279A patent/CR20220279A/es unknown
- 2020-12-11 IL IL293754A patent/IL293754A/en unknown
- 2020-12-11 JP JP2022537359A patent/JP7450724B2/ja active Active
- 2020-12-11 WO PCT/US2020/064512 patent/WO2021126695A1/en active Application Filing
- 2020-12-11 AU AU2020408139A patent/AU2020408139B2/en active Active
- 2020-12-11 US US17/785,758 patent/US20230102339A1/en active Pending
- 2020-12-11 CA CA3162245A patent/CA3162245A1/en active Pending
- 2020-12-11 MX MX2022007666A patent/MX2022007666A/es unknown
-
2022
- 2022-06-13 CO CONC2022/0008264A patent/CO2022008264A2/es unknown
- 2022-06-14 DO DO2022000122A patent/DOP2022000122A/es unknown
- 2022-06-15 CL CL2022001623A patent/CL2022001623A1/es unknown
- 2022-06-17 EC ECSENADI202248612A patent/ECSP22048612A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220279A (es) | 2022-07-03 |
| CO2022008264A2 (es) | 2022-07-08 |
| MX2022007666A (es) | 2022-07-19 |
| JP7450724B2 (ja) | 2024-03-15 |
| PE20221518A1 (es) | 2022-10-04 |
| CN114787183A (zh) | 2022-07-22 |
| JP2023506952A (ja) | 2023-02-20 |
| ECSP22048612A (es) | 2022-07-29 |
| TW202138385A (zh) | 2021-10-16 |
| WO2021126695A1 (en) | 2021-06-24 |
| AR120714A1 (es) | 2022-03-09 |
| AU2020408139A1 (en) | 2022-06-09 |
| IL293754A (en) | 2022-08-01 |
| JOP20220153A1 (ar) | 2023-01-30 |
| KR20220100676A (ko) | 2022-07-15 |
| CA3162245A1 (en) | 2021-06-24 |
| BR112022009396A2 (pt) | 2022-08-09 |
| TWI795698B (zh) | 2023-03-11 |
| CL2022001623A1 (es) | 2023-01-20 |
| AU2020408139B2 (en) | 2024-03-28 |
| US20230102339A1 (en) | 2023-03-30 |
| EP4077365A1 (en) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000123A (es) | Análogos de incretina y sus usos | |
| DOP2020000124A (es) | Análogos de incretina y sus usos | |
| DOP2022000122A (es) | Analogos de incretina y sus usos | |
| DOP2021000016A (es) | Compuestos coagonistas de gip/glp1 | |
| DOP2017000102A (es) | Coagonistas de los receptores de glucagón y de glp-1 | |
| AR103242A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| CL2023002808A1 (es) | Composiciones que contienen análogos de incretina y usos de estas | |
| ECSP17032341A (es) | Coagonistas de los receptores de glucagón y de glp-1 |